Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell immunoglobulin and mucin-domain receptor family (TIM) comprises cell-surface proteins with an N-terminal immunoglobulin-like domain and a mucin-like domain. They regulate immune responses by modulating T cell activity, recognizing phosphatidylserine on apoptotic cells, and serving as immune checkpoints (notably TIM-3). STRUCTURALLY, TIM family members are single-pass transmembrane glycoproteins with a conserved immunoglobulin V (IgV) domain and variable-length mucin domain. Biologically, these proteins participate in immune regulation, tolerance, and immunopathology; for example, TIM-3 is a negative immune regulator implicated in suppressing T cell function in cancer, while TIM-1 functions in allergy, infection, and kidney injury. Multiple therapeutic antibodies targeting TIM receptors, especially TIM-3, are in clinical development as anti-cancer agents via immunomodulation.
Immune checkpoint inhibition (antibodies block TIM-3 function to reverse T cell exhaustion and promote anti-tumor immunity); Modulation of T cell responses/inhibition of immunosuppression
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell immunoglobulin and mucin-domain receptor (TIM receptor).